<SEC-DOCUMENT>0001171843-24-001097.txt : 20240229
<SEC-HEADER>0001171843-24-001097.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229161006
ACCESSION NUMBER:		0001171843-24-001097
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240229
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		24703682

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_022924.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 18pt; text-align: center; margin: 4pt 0 0"><B>UNITED STATES </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 12pt 0 0"><B>FORM 6-K </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Date of report: 29 February 2024 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="font-size: 24pt; text-align: center; margin: 12pt 0 0"><B>GENFIT S.A. </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(Translation of registrant&rsquo;s name into English) </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>59120 Loos, France</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(Address of principal executive office) </B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">&#9746; Form 20-F &#9;&#9744; Form 40-F</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 8pt; font-size: 10pt; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 8pt">The contents of this report on Form 6-K (including Exhibit 99.1) are hereby incorporated by
reference into the registrant&rsquo;s registration statement on Form F-3 (File No. 333-271312) and registration statement on Form S-8
(File No. 333-271311) and related prospectuses, as such registration statements and prospectuses may be amended from time to time, and
to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed
or furnished. Information contained on, or that can be accessed through, any website included in Exhibit 99.1 is expressly not incorporated
by reference.</P>

<P STYLE="font-size: 10pt; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>EXHIBIT LIST </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="exh_991.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="exh_991.htm">Press Release dated 29 February 2024.</A></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: 29 February 2024</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: right; font-size: 10pt; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt 0; text-align: right; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><B><IMG SRC="hdr.jpg" ALT=""></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.7pt; color: #005477"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt 85.7pt; font-size: 10pt; text-align: center; color: #005477"><FONT STYLE="font-size: 12pt"><B>GENFIT Announces Revenues and Cash Position as of December 31, 2023</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: #005478"><B>&middot;</B></FONT></TD><TD STYLE="text-align: justify"><B>Cash
                                            and cash equivalents totaled &euro;77.8 million as of December 31, 2023</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 1.5pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: #005478"><B>&middot;</B></FONT></TD><TD STYLE="text-align: justify; padding-right: 5.85pt"><B>Revenues
                                            amounted to &euro;28.6 million as of December 31, 2023 including a milestone payment of &euro;13.3
                                            million</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; color: #005478"><B>&middot;</B></FONT></TD><TD STYLE="text-align: justify"><B>Upcoming
                                            FDA PDUFA action date for elafibranor in PBC: June 10, 2024</B></TD></TR></TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><FONT STYLE="color: #005278"><B>Lille (France), Cambridge
(Massachusetts, United States), Zurich (Switzerland), February 29, 2024 </B></FONT><B>- GENFIT (Nasdaq and Euronext: GNFT)</B>, a late-stage
biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced
its cash position as of December 31, 2023 and revenues for 2023.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt; font-size: 10pt; text-align: justify"><B>Cash Position</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 5.9pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">As of December 31, 2023, the Company&rsquo;s cash and cash
equivalents amounted to &euro;77.8 million compared with &euro;140.2 million as of December 31, 2022. As of September 30, 2023, cash and
cash equivalents totaled &euro;93.9 million.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">This amount does not include the receipt in February 2024
of a &euro;13.3 million milestone payment from Ipsen, which was invoiced in December 2023, triggered by the acceptance of the New Drug
Application (NDA) filing by the US Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) by the European Medicines
Agency (EMA) for accelerated approval of elafibranor in Primary Biliary Cholangitis (PBC) in December 2023.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">As previously indicated in past communications<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>,
in 2024 GENFIT expects to receive <FONT STYLE="color: #0D0D0D">total milestone payments of approximately &euro;89 million (including
the &euro;13.3 milestone already received in February 2024), subject to the approval and commercialization of elafibranor in PBC</FONT>.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.6pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">The decrease in cash and cash equivalents between September
30, 2023, and December 31, 2023, takes into account our continued research and development efforts, notably for:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 5.75pt">UNVEIL-IT&trade;, our Phase 2 clinical trial evaluating VS-01 in Acute-on-Chronic Liver Failure (ACLF);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our cholangiocarcinoma program evaluating GNS561;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">___________________</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><FONT STYLE="color: Black"><SUP>1</SUP> GENFIT Updates 2024 Outlook Following Acceptance
of Elafibranor Filings in Primary Biliary Cholangitis (PBC)</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>

<P STYLE="margin: 0pt 7.6pt 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></P>

<P STYLE="margin: 0pt 7.6pt 0pt 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><IMG SRC="hdr.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 44.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ACLF program evaluating NTZ;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 44.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our non-clinical trial of SRT-015 in ACLF; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 44.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 5.8pt">ELATIVE&reg;, specifically the portion of the Phase 3 clinical trial evaluating elafibranor in PBC that
has not yet been transferred to Ipsen.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">We expect that our existing cash and cash equivalents will
enable us to fund our operating expenses and capital expenditure requirements until approximately the fourth quarter of 2025. This is
based on current assumptions and programs, and does not include exceptional events. This estimation includes our expectations to receive
future milestone revenue in 2024, <FONT STYLE="color: #0D0D0D">subject to approval by applicable regulatory authorities and </FONT>US
and European commercial launches of elafibranor in PBC by Ipsen, representing a total of approximately &euro;75.2 million.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.55pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><B>Revenues</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">Revenues for 2023 amounted to &euro;28.6 million compared
to &euro;20.2 million for the same period in 2022.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">Of the &euro;28.6 million, &euro;13.3 million was attributable
to a milestone payment invoiced to Ipsen in December 2023 in accordance with the Collaboration and Licensing agreement signed in December
2021. This milestone payment was earned following the NDA filing acceptance by the FDA and MAA filing acceptance by the EMA for accelerated
approval of elafibranor. &euro;8.7 million in revenue was attributable to the partial recognition of the &euro;40.0 million deferred income
as described below. &euro;6.5 million in revenue was generated from the services rendered under the Transition Services Agreement and
Part B Transition Services Agreement, signed in April 2022 and September 2023 respectively by GENFIT and Ipsen, in order to facilitate
the transition of certain services related to the Phase 3 ELATIVE&reg; clinical trial until the complete transfer of the responsibility
of the trial to Ipsen. &euro;0.1 million was attributable to other ancillary activities.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">Of the &euro;20.2 million in revenues for 2022, &euro;15.9
million was attributable to the partial recognition of the &euro;40.0 million deferred income per IFRS <FONT STYLE="font-size: 10pt"><SUP>2
</SUP></FONT>15 in accordance with the Collaboration and Licensing Agreement signed with Ipsen in 2021. &euro;1.0 million in revenue
was generated from services rendered by GENFIT to Ipsen in accordance with the Transition Services Agreement signed in 2022. &euro;3.3
million was recognized as revenue in accordance with the Inventory Purchase Agreement signed with Ipsen in 2022, under which the Company
sold almost all of its remaining stock of elafibranor&rsquo;s active ingredient and drug products for the ELATIVE<FONT STYLE="font-size: 10pt">&reg;
</FONT>Phase 3 clinical trial to Ipsen.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 5.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">___________________</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><SUP>2</SUP> International Financial Reporting Standards</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>
<P STYLE="margin: 0pt 6.05pt 0pt 0pt; font-size: 10pt"></FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; text-align: justify; color: #005477"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #005477"><FONT STYLE="color: Black"><IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; text-align: justify; color: #005477"><FONT STYLE="color: Black"></FONT></P>







<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left; color: #005477"><FONT STYLE="color: Black"><IMG SRC="hdr.jpg" ALT=""></FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><B>Upcoming FDA PDUFA<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT> Action Date
for Elafibranor in PBC: June 10, 2024</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">Regulatory filing acceptance has been obtained in the US,
Europe and the United Kingdom<FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT> and a Priority Review has been granted for an NDA by the
FDA for elafibranor in PBC with a PDUFA target action date of June 10, 2024.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 5.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><B>Upcoming Financial Communications</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">The Company will release its full-year 2023 financial results
on April 4, 2024. The 2023 Universal Registration Document, the 2023 Annual Financial Report (included in the 2023 Universal Registration
Document), and the Annual Report on Form 20-F will be published by the end of April 2024.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 5.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt; color: #005478"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">GENFIT is a late-stage biopharmaceutical company dedicated
to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. GENFIT is
a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
Today, GENFIT has a growing and diversified pipeline with programs at various development stages. The Company&rsquo;s area of focus is
Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise consists of five assets in development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE.
These are all based on differentiated mechanisms of action leveraging complementary pathways. Other assets target other life-threatening
disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA). GENFIT&rsquo;s track record
in bringing early-stage assets with high potential to late development and pre- commercialization stages is highlighted in the successful
52-week Phase 3 ELATIVE&reg; trial evaluating elafibranor in PBC. Beyond therapeutics, GENFIT&rsquo;s pipeline also includes a diagnostic
franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH) previously known as nonalcoholic steatohepatitis (NASH)
and ammonia. GENFIT has facilities in Lille and Paris (France<FONT STYLE="color: Black">), Zurich (Switzerland) and Cambridge, MA (USA).
GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext&rsquo;s regulated market
in Paris (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT&rsquo;s largest shareholders and holds 8% of the company&rsquo;s
share capital. For more information, visit www.genfit.com</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 5.9pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">___________________</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">3 Prescription Drug User Fee Act</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><FONT STYLE="color: Black"><SUP>4</SUP> Ipsen confirms U.S.
FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC</FONT></P><P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;<IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">3</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left; color: #005477"><FONT STYLE="color: Black"><IMG SRC="hdr.jpg" ALT=""></FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="margin: 0pt; font-size: 10pt; color: #005478"><B>FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt; color: #005478"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 5.55pt 0pt 0pt; font-size: 10pt; text-align: justify">This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not
limited to statements about the Company&rsquo;s eligibility to receive future milestone payments from Ipsen relating to the development
and commercial launch of elafibranor in PBC, approval of elafibranor in PBC and potential commercialization as early as 2024, and expected
cash runway. The use of certain words, including &ldquo;believe&rdquo;, &ldquo;potential,&rdquo; &ldquo;expect&rdquo;, &ldquo;target&rdquo;,
&ldquo;may&rdquo; and &ldquo;will&rdquo; and similar expressions, is intended to identify forward-looking statements. Although the Company
believes its expectations are based on the current expectations and reasonable assumptions of the Company&rsquo;s management, these forward-looking
statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things,
the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and
results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and
worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations,
our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the
Company&rsquo;s public filings with the AMF, including those listed in Chapter 2 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s
2022 Universal Registration Document filed with the AMF on April 18, 2023, which is available on the Company&rsquo;s website (www.genfit.com)
and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission
(&ldquo;SEC&rdquo;) including the Company&rsquo;s 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 and subsequent
filings and reports filed with the AMF or SEC, including the Half- Year Business and Financial Report at June 30, 2023 or otherwise made
public, by the Company. In addition, even if the Company&rsquo;s results, performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments
in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required
by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether
as a result of new information, future events or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.55pt 0pt 5.9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black"></FONT></P><P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P><P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;<IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">4</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left; color: #005477"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: left; color: #005477"><FONT STYLE="color: Black"><IMG SRC="hdr.jpg" ALT=""></FONT></P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font-size: 10pt; color: #005478"><B>CONTACT</B></P>

<P STYLE="margin: 0pt 0 0pt 5.9pt; font-size: 10pt; color: #005478"></P>
<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black"></FONT></P><P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font-size: 10pt"><B>GENFIT</B> | Investors</P>

<P STYLE="margin: 0pt 0 0pt 5.9pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: Black">Tel: +33 3 2016 4000 |</FONT> <FONT STYLE="color: Black">investors@genfit.com</FONT></P>

<P STYLE="margin: 0pt 0 0pt 5.9pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt; font-size: 10pt"><B>PRESS RELATIONS</B> | Media</P>

<P STYLE="margin: 0pt 0 0pt 5.9pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt; font-size: 10pt">Stephanie Boyer &ndash; Press relations | Tel: +333 2016 <FONT STYLE="color: Black">4000
| stephanie.boyer@genfit.com</FONT></P>

<P STYLE="margin: 0pt 0 0pt 5.9pt; font-size: 10pt">&nbsp;</P>


<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;<IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></FONT></P>

<P STYLE="text-align: right; margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">5</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ R0,@ P$1  (1 0,1 ?_$ ,$   $% 0$!
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M:8=3(HH!#0##0 U]*1H#JK&IR>"M+O3E%B4BJE2,FF#P: 6@$O0'4 AH!BJ
M&J@&%9'2IL.'H=)%0H\+[Z96G;KTR(:"<F@XXTE.%('7JDF[J [=01"NDJ*C
MDBOW+&O52OQ"HWC32J=#=D^^C5&XB6A6^K [RTGLK05WDBU-&'>6.Z@\')0*
M 4IL* :01K0 RLBC!F%>M .2VI1O066)*U*5<U=9BM*45B]<7)6^B>VOI7+L
M[M$A*KUFZ8DLVH Q([=*N)VAI(&H-7&&T"6\ ;7KIXZXN6(,A_6NS5C41UZ]
M4E72I.V]%.*>;F&D*L>M9TU?(S@*; TX*JI<Q;B3;6]:1ELI):0J^ZM654TA
M&U7OH9A6H#B* ;;2@&*&M!NMI2,,BBKB.Z*BG "-*FM(<@6J*N)".HHBDQKX
M13(8"PH(\4$<*1")-"3NM('$6(H!U ** $XH6H" ZH;O;W4FL.:3=0JH*GH9
M!2*J)&BLK#@M3#;\>FK: "KBBAMX>00XA(W:U.#RMXSWMHP$M+X[ZFF4O FW
M;3,I-Q3H174Z7I9"*20:8%;>4CH:FZY);8N3YDR.+Z^8G3\-8[<>%Z[-B3:H
M;!K.E2:*YJ:FKCFQK24F-=*J(HP%41P&E,D3(Y3&X]OS)TEN,@]/,4 3[AU-
M8<_D\?%,[[37\VO#X_)RW&FMV_)0/>H_%&E[?/=6#T4EI6T^XFU>;O\ ?_%U
MOK;_ "=^OV3R;\)_5*@\XXO-4$-SDMK.@0\"W_:K3^VM^#[SXO)TF^+^/1ER
M_:?(X^MUS^75>)6"D*20I)%P1J#7J2YZQY]AP501"J@&$T&$XK2IHB$Z+JJ6
MD<TG6ED5+15RLZ>":N$>%4#)P50"WH#KT EZ :30 UG2F 5 FE8"IN*G!GA5
M& 4+IX(NZC ."A2INW4E0FZD'%8IIII=%.$87 384P<.M(U-R=82U%).F]7X
MA2L/*M:7N'LJ<%E("PD5KJR(%W-6*?NTJB)N% <%=M -4^D=:""5)0#UIP K
M?0>AIDYI22K4T!/9V[=*SMZEE@D.(!LHZ5IL4&04;M*X^2-M4MH@FN6N[1-:
M M6=="0@"VAI -PJ!IRE3"LFMM:QH3ERX36VOJX>972RH+O7H:>CG0G'^VF%
M9.?%CK3H8_+E:GM#VUGL8#:%$"_=2ABJ2 G6KE9V*Z78W'95RL[%'+)W>ZJE
M18!NN:K*>TA52[AVDW49&"$BF>##8U*I"$V'?0I'<TZ_@J; "4"HL:PJ4"]1
M52)#8%_91%);=K56"R,FU $%A1:6'#4TBP(FUJ"P?84DG)%Q0#P !K0#2H &
M@(DAP;=*%Q7N.672:I495R#3U35PPV5 6JV:V@0-Q&E:1*^;BJ:2"!THL T?
M)N,N)3NJ<*RTL'-!3:03K2P,K:/D4J3UHP<2&9.XTE1+\T6O>IIF*<N*)"J$
MM:0H^RJD2&J6V+T\!.PDG?DH@2#]ZD?VU&]Z+U>AZ]M<U;FE)J:J!+3K4U4,
M2G6I6EM=*N(HZ:I+$<@]8>!XC*R\'*GO?U*.E(6W%96^HK5_U:"@*'F)[0>E
M;?2<F^N9TRYKYO'IMB]<(^/=1/0,CB^.*\>IR>>46U6[RAS<OZ*^:Y?&VTWO
M;PR[3_7R;2_\WT?%Y.O)QS/+9K?]&FMG_)!SD1G,JVR<C_4\FPA2(L/$Q[LM
MDZV6X;BU^\BO-\SAGD=-M_F<DG37CUZ3^;T?%Y+P_MT[-+ZWDVZW\HP2T+0M
M3:QM6@E*TGL(T(KY7;6RXKZ&669BZX]R[+81U(:<+T._[R(X24$?F_DGW5Z7
MV_[MR^->ESI_;_'HX/-^V\7D3K,;?W?QZO6\1FX65@MS(BKMJT4@_$A0ZI4.
M\5^A^'Y>GD<<WT]/^#XCRO&WX-[IOZ_\4W>#72YW5-H#6+U-7( INIJHY*+4
M0ZD)&E4SIUM*N)=3!2J@9=NH!;T!U (: ;8&@.VB@$*!2!-E ,*3>F'#04!V
MZIINW4E0MZ0-4:"H*R:N$>RGM-%(<)I&H^6-J4Q%MV+5^(54*J5I+@%--)YS
M@58UI$CH>TH(XOVHP'&2 *>$T(RB>E41A<4: ;M4: :&U7IE@1"5#6I/"='4
MK:*SJ:P#D9R_6M*J)<1@DB_97/O&VJP0C:;WTKFNCIUV&2\.PUCMJWUV%3(
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M?PO(U2J_=1W%A897$0\=BH#S3I7.DI*GV_LI3W4#"/#Y!)0/E3^]:4+;7/$
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MJ&0H:5R=[L[%[BX=R-*SVV:ZZ-/%A) 2+5A;AM-%BQ$3NU&E3W9.ZM+BH3(
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ME^HDQR9_QGC&<=Y9:^1\@ ;[D^9>RW.FE</-IQS'9<O4\??EN>^8>>>@8_\
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MX)F7QCZA82&1N;W?G)TI8:8B'GL1)Q@#"5"1%.J)37PK'M'93PSV5>.BO2I
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C&NB.?8?NJD$-(!.=M*KB$]451K52I,:Z5<14M'2K0?3)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B SH# 2(  A$! Q$!_\0
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MOQ%JFMP2W#7.I;/.1V4HNT8&T  C\2:G\26LU[X7U6UMHS)/-:2QQH#]YBA
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M&<Y/K1H>B6V@:>UG:O*\;323$RD$Y=BQZ <9-"VU_K7_ "!^7]:?YFE1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
